Desensitization and Beyond: How Highly Sensitized Patients Can Still Receive Transplants

Patients with high levels of anti-HLA antibodies face severely limited donor options. Today, a combination of advanced paired exchange algorithms, modern desensitization protocols, and next-generation therapeutics are expanding access to life-saving transplantation.

Some transplant candidates have antibodies against a wide range of HLA types, making it extremely difficult to find a compatible donor. These "highly sensitized" patients can wait years longer than average for a transplant, and some never receive one. For decades, this was an insurmountable barrier. Today, clinical pathways exist to help these patients cross the transplant finish line by either navigating around the antibodies or actively disarming them.

Who becomes highly sensitized?

Sensitization occurs when the immune system is exposed to foreign HLA molecules and produces antibodies against them. The three most common sensitizing events are:

• Previous transplants: A patient whose first transplant failed has been exposed to the donor's HLA molecules and has likely developed antibodies against them, as well as cross-reactive antibodies against related HLA types.
• Blood transfusions: Red blood cell transfusions can expose the recipient to HLA molecules from the donor's white blood cells, triggering antibody production. While leukocyte reduction (filtering white blood cells) has mitigated this risk, it has not completely eliminated it.
• Pregnancies: During pregnancy, the mother's immune system is exposed to paternal HLA molecules expressed by the fetus. Approximately 1 in 10 women develop anti-HLA antibodies after their first pregnancy, and the rate increases with subsequent pregnancies, to roughly 1 in 3 among women with four or more.

A patient's sensitization level is quantified by the Calculated Panel Reactive Antibody (CPRA) score, which estimates the percentage of potential donors against whom the patient has preformed antibodies. A CPRA of 99 percent means the patient has antibodies against the HLA molecules carried by 99 percent of the donor population, leaving only a 1 percent chance of finding a compatible match by random allocation.

Overcoming Sensitization: Clinical and Algorithmic Strategies

When a patient is highly sensitized, transplant centers deploy a mix of algorithmic, immunological, and pharmacological strategies to make a transplant possible:

1. Paired Organ Exchange (Algorithmic Matching)
Before subjecting a patient to the physical toll of medical desensitization, the safest approach is to find a donor the patient isn't sensitized to. In kidney transplantation, Kidney Paired Donation (KPD) utilizes massive computational pools to arrange multi-way donor swaps. If a willing living donor is incompatible with their intended recipient, algorithms can map complex chains of exchanges across multiple pairs, finding a compatible match even for highly sensitized patients.

2. Traditional Desensitization Protocols
When a compatible donor cannot be found, clinical desensitization aims to actively lower anti-HLA antibody levels to allow transplantation:

• Plasmapheresis/Plasma exchange: This procedure physically filters antibodies from the patient's blood by discarding the antibody-rich plasma and returning the blood cells with a replacement fluid.
• Intravenous immunoglobulin (IVIg): High-dose IVIg provides immunomodulatory effects that can neutralize anti-HLA antibodies and dampen broader immune responses.
• Cellular Depletion: Drugs like rituximab (anti-CD20 therapy) target the B cells that act as precursors to antibody-producing plasma cells, while proteasome inhibitors like bortezomib attack the mature plasma cells directly, shutting down the "factories" producing the problematic antibodies.

3. Next-Generation Therapeutics
Recent breakthroughs have dramatically expanded the desensitization toolkit for the most challenging cases:

• IgG-degrading enzymes (Imlifidase): Rather than just suppressing antibody production, imlifidase rapidly cleaves and inactivates existing IgG antibodies in the bloodstream. This creates a temporary, critical window of immunological safety, allowing highly sensitized patients to receive a transplant that would otherwise trigger immediate hyperacute rejection.
• Complement Inhibitors (Eculizumab): Even with desensitization, antibodies can still bind to the new organ. Eculizumab blocks the downstream "complement cascade"—the destructive inflammatory process triggered by those antibodies. It has been studied as a way to protect the organ from early antibody-mediated damage.

The Trade-offs

Medical desensitization is not without significant risks. The treatments carry heavy side effects, particularly severe infection risks due to profound immune depletion. Furthermore, even when successful, transplants performed after desensitization carry higher rates of antibody-mediated rejection (AMR) and generally have lower long-term graft survival compared to standard, non-sensitized transplants.

However, the clinical calculus is straightforward: for a highly sensitized patient who may never receive a compatible organ otherwise, the benefits of desensitization and transplantation typically outweigh the high mortality risks of remaining on dialysis indefinitely or facing end-stage heart or lung failure.

Where Better Matching Fits

For sensitized patients, donor selection is the ultimate variable. Because these patients already face a higher baseline risk of rejection, ensuring the tightest possible match among their limited options is paramount.

This is an area where the granularity of molecular-level mismatch analysis matters most. When a patient has an extensive antibody profile, the goal is not just finding a donor who yields a negative crossmatch today, but identifying which crossmatch-negative donor presents the lowest molecular-level risk for the future.

At Immunomatics, our predictive models are designed to answer exactly that question. By analyzing structural mismatches at the peptide and amino-acid levels, we aim to empower clinicians to confidently select the safest possible donor for their most complex patients—minimizing the need for harsh desensitization when possible, and optimizing the odds of long-term graft survival when it is required.